Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: A single-center experience in Korea [2]

International Journal of Hematology

Volumn 83, Issue 3, 2006, Pages 277-278

  Choi, Su Mi ^a   Lee, Dong Gun ^a   Choi, Jung Hyun ^a   Yoo, Jin Hong ^a   Kim, Yoo Jin ^a   Park, Sun Hee ^a   Min, Chang Ki ^a   Lee, Seok ^a   Kim, Hee Je ^a   Kim, Dong Wook ^a   Lee, Jong Wook ^a   Min, Woo Sung ^a   Shin, Wan Shik ^a,b   Kim, Chun Choo ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

THYMOCYTE ANTIBODY; LYMPHOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; DONOR; DRUG EFFECT; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; LETTER; LEUKOCYTE COUNT; RISK FACTOR; RISK REDUCTION; ALLOTRANSPLANTATION; COMPARATIVE STUDY; CYTOMEGALIC INCLUSION BODY DISEASE; DONOR SELECTION; FEMALE; INCIDENCE; KOREA; LIVING DONOR; MALE; MONITORING; NOTE; PROSPECTIVE STUDY; STEM CELL TRANSPLANTATION;

ANTILYMPHOCYTE SERUM; CYTOMEGALOVIRUS INFECTIONS; DONOR SELECTION; FEMALE; HUMANS; INCIDENCE; KOREA; LIVING DONORS; MALE; MONITORING, PHYSIOLOGIC; PROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 33745933146     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02985486     Document Type: Letter

References (6)

1. Mori T, Aisa Y, Nakazato T, Ikeda Y, Okamoto S. Risk-adapted pre-emptive therapy for cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2005;81:439-440.
2. Choi SM, Lee DG, Choi JH, et al. Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea. Int J Hematol. 2005;81:69-74.
3. Asano-Mori Y, Oshima K, Sakata-Yanagimoto M, et al. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;36:813-819.
4. Von Muller L, Hampl W, Hinz J, et al. High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay. J Clin Microbiol. 2002;40:2285-2287.
5. Mori T, Okamoto S, Matsuoka S, et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;25:765-769.
6. Kanda Y, Mineishi S, Saito T, et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant. 2001;27:437-444.